Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s

Multiple myeloma (MM) is the second most prevalent hematologic malignancy. Although the use of bortezomib (BTZ) significantly improves MM therapy, intrinsic and acquired drug resistance to BTZ remains a major clinical problem. In this study, we find that Cdc37, a key co-chaperone of Hsp90, is downre...

Descripción completa

Detalles Bibliográficos
Autores principales: Zang, Meirong, Guo, Jiaojiao, Liu, Lanting, Jin, Fengyan, Feng, Xiangling, An, Gang, Qin, Xiaoqi, Wu, Yangbowen, Lei, Qian, Meng, Bin, Zhu, Yinghong, Guan, Yongjun, Deng, Shuhui, Hao, Mu, Xu, Yan, Zou, Dehui, Wu, Minghua, Qiu, Lugui, Zhou, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058164/
https://www.ncbi.nlm.nih.gov/pubmed/32139666
http://dx.doi.org/10.1038/s41389-020-0216-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058164/
https://www.ncbi.nlm.nih.gov/pubmed/32139666
http://dx.doi.org/10.1038/s41389-020-0216-1

Ejemplares similares